Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of ACT-385781A (EFI) in pulmonary arterial hypertension
NL-OMON39075Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Dec 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Treatment-emergent adverse events up to 24 hours post end of treatment, Adverse events leading to premature discontinuation of study drug and 1 more. Started Dec 2011; status: active, not recruiting.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON39075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39075.